Navigation Links
Novo Nordisk Appoints Alan C. Moses as Chief Medical Officer Worldwide

PRINCETON, N.J., Jan. 9 /PRNewswire-FirstCall/ -- Novo Nordisk, a healthcare company with an 84-year history of innovation and achievement in diabetes care, today announced the appointment of Alan C. Moses, M.D. as vice president, chief medical officer worldwide. Moses is currently the chief medical officer of Novo Nordisk Inc., the company's U.S. affiliate.

"Alan has the unique talent to integrate the science of discovery with new drug development -- a critical asset that will deepen Novo Nordisk's leadership position in changing diabetes," said Mads Krogsgaard Thomsen, executive vice president and chief science officer for Novo Nordisk A/S. "The broadening of Novo Nordisk's diabetes therapeutic portfolio with the development of liraglutide and other novel molecules in the pipeline, and the increasing importance of the U. S. to the Novo Nordisk business, requires a leader with clinical and research expertise to assume the role of chief medical officer."

In the newly expanded role, Moses will work closely with senior colleagues in Denmark to serve as the principle voice of clinical science for the company worldwide, providing clinical and medical affairs expertise.

"Novo Nordisk and the diabetes community in the U.S. have been fortunate to have Alan lead the efforts for the company in changing diabetes, and now, with his expanded responsibilities, the world will benefit from Alan's passion for research and advocacy for finding better ways for people to live with the disease," said Dr. Henrik Rasmussen, vice president of clinical development, medical and regulatory affairs, Novo Nordisk Inc.

Moses was formerly senior vice president and chief medical officer at the Joslin Diabetes Center and joined Novo Nordisk in April 2004 as associate vice president of medical affairs and since then has also assumed responsibility for clinical research in diabetes. Prior to joining Novo Nordisk, Dr. Moses spent 23 years at Harvard Medical School-affiliated institutions where he rose to the rank of Professor of Medicine. He has written more than 100 peer- reviewed articles on the treatment of diabetes and has been recognized both locally and nationally for his research in diabetes and growth factors.

Moses received a Bachelor of Science from Duke University and a Medical Doctorate from Washington University School of Medicine prior to training at Barnes Hospital in St. Louis, the National Institutes of Health in Bethesda, Md., and Tufts-New England Medical Center in Boston. He is board certified by the American Board of Internal Medicine and has a subspecialty certification in Endocrinology and Metabolism.

About Novo Nordisk

Novo Nordisk is a healthcare company with an 84-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 25,800 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit; for United States information, visit

SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Novo Nordisk Applauds Adoption of World Diabetes Day Resolutions by U.S. Congress
2. Novo Nordisk Inc. Announces Exclusive Agreement With Sciele Pharma, Inc. to Market Prandin(R)
3. Novo Nordisk Increased Operating Profit by 11% in the First Nine Months of 2007 Based on a 9% Sales Increase and an Improved Gross Margin
4. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
5. Ikaria Appoints Daniel Tasse as President and Chief Executive Officer
6. SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer
7. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
8. Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
9. Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO
10. Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
11. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
Post Your Comments:
(Date:11/24/2015)...  Clintrax Global, Inc., a worldwide provider of clinical research services ... that the company has set a new quarterly earnings record in ... growth posted for Q3 of 2014 to Q3 of 2015.   ... , with the establishment of an Asia-Pacific ... United Kingdom and Mexico , ...
(Date:11/24/2015)... ... 2015 , ... This fall, global software solutions leader SAP and AdVenture Capital ... and pitch their BIG ideas to improve health and wellness in their schools. , ... win the title of SAP's Teen Innovator, an all-expenses paid trip to Super Bowl ...
(Date:11/24/2015)... Massachusetts , November 24, 2015 SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... , Chief Financial Officer, will participate in the Piper Jaffray 27 ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. ...
(Date:11/24/2015)... -- Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting ... Israel time, at the law offices of ... th Floor, Tel Aviv, Israel . ... Izhak Tamir to the Board of Directors; , election of ... approval of an amendment to certain terms of options granted to our ...
Breaking Biology Technology:
(Date:11/18/2015)... New York , November 18, 2015 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2021. According to the ... in 2014 and is anticipated to reach US$29.1 bn ... to 2021. North America ...
(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
Breaking Biology News(10 mins):